Phase Ib Trial of Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Malignancies
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; XL 888 (Primary)
- Indications Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Pancreatic cancer
- Focus Adverse reactions
- 26 Feb 2018 Trial design presented at the 2018 Gastrointestinal Cancers Symposium.
- 05 Jul 2017 Planned End Date changed from 1 Sep 2023 to 1 Jun 2023.
- 05 Jul 2017 Planned primary completion date changed from 1 Sep 2021 to 1 Jun 2021.